SEARCH

SEARCH BY CITATION

References

  • Adler AI, Stratton IM, Neil HA et al (2000). Association of systolic blood pressure with macrovascular and microvascular complications of type 2 diabetes (UKPDS 36): prospective observational study. BMJ 321: 412419.
  • Aljada A, Ghanim H, Mohanty P, Kapur N, Dandona P (2002). Insulin inhibits the pro-inflammatory transcription factor early growth response gene-1 (Egr)-1 expression in mononuclear cells (MNC) and reduces plasma tissue factor (TF) and plasminogen activator inhibitor-1 (PAI-1) concentrations. J Clin Endocrinol Metab 87: 14191422.
  • Allen PF, McMillan AS (2003). A review of the functional and psychosocial outcomes of edentulousness treated with complete replacement dentures. J Can Dent Assoc 69: 662662e.
  • Amori RE, Lau J, Pittas AG (2007). Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 298: 194206.
  • Bagdade JD, Root RK, Bulger RJ (1974). Impaired leukocyte function in patients with poorly controlled diabetes. Diabetes 23: 915.
  • Buchanan TA, Xiang AH, Peters RK et al (2002). Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51: 27962803.
  • Chiasson JL, Josse RG, Gomis R, Hanefeld M, Karasik A, Laakso M (2002). Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomized trial. Lancet 359: 20722077.
  • Collins R, Armitage J, Parish S, Sleigh P, Peto R (2003). Heart Protection Collaborative Group. MRC / BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 361: 20052016.
  • Coutinho M, Gerstein HC, Wang Y, Yusuf S (1999). The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 22: 233240.
  • Dandona P, Aljada A, Mohanty P et al (2001). Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 86: 32573265.
  • Drucker DJ, Nauck MA (2006). The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368: 16961705.
  • Emslie-Smith AM, Boyle DIR, Evans JMM, Sullivan F, Morris AD (2001). Contraindications to metformin therapy in patients with Type 2 diabetes – a population-based study of adherence to prescribing guidelines. Diabet Med 18: 483488.
  • Fourlanos S, Perry C, Stein MS, Stankovich J, Harrison LC, Colman PG (2006). A clinical screening tool identifies autoimmune diabetes in adults. Diabetes Care 29: 970975.
  • Furnary AP, Zerr KJ, Grunkemeier GL, Starr A (1999). Continuous intravenous insulin infusion reduces the incidence of deep sternal wound infection in diabetic patients after cardiac surgical procedures. Ann Thorac Surg 67: 352360.
  • Gerich J, Raskin P, Jean-Louis L, Purkayastha D, Baron A (2005). PRESERVE: two year efficacy and safety of initial combination therapy with nateglinide or glyburide plus metformin. Diabetes Care 28: 20932100.
  • Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. The DECODE Study Group on behalf of the European Diabetes Epidemiology Group (1999). Diabetes epidemiology: collaborative analysis of diagnostic criteria in Europe. Lancet 354: 617621.
  • Goutzanis L, Vairaktaris E, Yapijakis C et al (2007). Diabetes may increase risk for oral cancer through the insulin receptor substrate-1 and focal adhesion kinase pathway. Oral Oncol 43: 165173.
  • Grossi SG, Skrepcinski FB, DeCaro T et al (1997). Treatment of periodontal disease in diabetics reduces glycated hemoglobin. J Periodontol 68: 713719.
  • Hansson L, Zanchetti A, Carruthers SG et al (1998). Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 351: 17551762.
  • Home PD, Pocock SJ, Beck-Nielsen H et al (2007). Rosiglitazone evaluated for cardiovascular outcomes – an interim analysis. N Engl J Med 357: 2838.
  • Jones JA, Miller DR, Wehler CJ et al (2007). Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study. J Clin Periodontol 34: 4652.
  • Kahn SE, Haffner SM, Heise MA et al (2006). Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. N Engl J Med 355: 24272443.
  • Knowler WC, Barrett-Connor E, Fowler SE et al (2002). Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346: 393403.
  • LaRosa JC, Grundy SM, Waters DD et al (2005). Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med 352: 14251435.
  • Löe H (1993). Periodontal disease: the sixth complication of diabetes mellitus. Diabetes Care 16: 329334.
  • Loos BG, Craandijk J, Hoek FJ, Wertheim-van Dillen PM, Van Der Velden U (2000). Elevation of systemic markers related to cardiovascular diseases in the peripheral blood of periodontitis patients. J Periodontol 71: 15281534.
  • Magnotti MA, Rayfield EJ (2007). An update on insulin injection devices. Insulin 2: 173181.
  • Narayan KM, Boyle JP, Thompson TJ, Sorensen SW, Williamson DF (2003). Lifetime risk for diabetes mellitus in the United States. JAMA 290: 18841890.
  • Nathan DM, Cleary PA, Backlund JY et al (2005). Intensive diabetes treatment and cardiovascular disease in patients with type 1 Diabetes. The DCCT / EDIC Study Research Group. N Engl J Med 353: 26432653.
  • Nissen SE, Wolski K (2007). Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N Engl J Med 356: 24572471.
  • Pan XR, Li GW, Hu YH et al (1997). Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance: the Da Qing IGT and Diabetes Study. Diabetes Care 20: 537544.
  • Perner A, Nielsen SE, Rask-Madsen J (2003). High glucose impairs superoxide production from isolated blood neutrophils. Intensive Care Med 29: 642645.
  • Petersen PE (2003). The World Oral Health Report 2003: continuous improvement of oral health in the 21st century – the approach of the WHO Global Oral Health Programme. Community Dent Oral Epidemiol 31: 323.
  • Petrou-Amerikanou C, Markopoulos AK, Belazi M, Karamitsos D, Papanayotou P (1998). Prevalence of oral lichen planus in diabetes mellitus according to the type of diabetes. Oral Dis 4: 3740.
  • Promsudthi A, Pimapansri S, Deerochanawong C, Kanchanavasita W (2005). The effect of periodontal therapy on uncontrolled type 2 diabetes mellitus in older subjects. Oral Dis 11: 293298.
  • Resnick HE, Foster GL, Bardsley J, Ratner RE (2006). Achievement of American Diabetes Association clinical practice recommendations among U.S. adults with diabetes, 1999–2002: the National Health and Nutrition Examination Survey. Diabetes Care 29: 531537.
  • Rodrigues DC, Taba MJ, Novaes AB, Souza SL, Grisi MF (2003). Effect of non-surgical periodontal therapy on glycemic control in patients with type 2 diabetes mellitus. J Periodontol 74: 13611367.
  • Roglic G, Unwin N, Bennett PH et al (2005). The burden of mortality attributable to diabetes: realistic estimates for the year 2000. Diabetes Care 28: 21302135.
  • Rosenstock J, Hassman DR, Madder RD et al (2004). Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 12651270.
  • Salpeter S, Greyber E, Pasternak G, Salpeter E (2006). Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. Cochrane Database Syst Rev 1: CD002967.
  • Saremi A, Nelson RG, Tulloch-Reid M, Hanson RL, Sievers ML, Taylor GW, Shlossman M, Bennett PH, Genco R, Knowler WC (2005). Periodontal disease and mortality in type 2 diabetes. Diabetes Care 28: 2732.
  • Selvin E, Marinopoulos S, Berkenblit G et al (2004). Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 141: 421431.
  • Sheiham A, Steele JG, Marcenes W, Tsakos G, Finch S, Walls AW (2001a). Prevalence of impacts of dental and oral disorders and their effects on eating among older people; a national survey in Great Britain. Community Dent Oral Epidemiol 29: 195203.
  • Sheiham A, Steele JG, Marcenes W et al (2001b). The relationship among dental status, nutrient intake, and nutritional status in older people. J Dent Res 80: 408413.
  • Standards of Medical Care in Diabetes (2007). American Diabetes Association. Diabetes Care 30: S4S41.
  • Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD (1994). Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 94: 11721179.
  • Stewart JE, Wager KA, Friedlander AH, Zadeh HH (2001). The effect of periodontal treatment on glycemic control in patients with type 2 diabetes mellitus. J Clin Periodontol 28: 306310.
  • Tataranni PA, Bogardus C (2004). Metabolic abnormalities in the development of type 2 diabetes mellitus. In: LeRoithD, OlefskyJM, TaylorSI eds. Diabetes mellitus: a fundamental and clinical text. 3rd edn. Lippincott Williams & Wilkins: Philadelphia, pp. 797807.
  • Taylor GW, Burt BA, Becker MP et al (1996). Severe periodontitis and risk for poor glycemic control in patients with non-insulin-dependent diabetes mellitus. J Periodontol 67: 10851093.
  • The DCCT Research Group (1993). The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329: 977986.
  • The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone medication) Investigators (2006). Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. Lancet 368: 10961105.
  • Trovati M, Anfossi G, Massucco P et al (1997). Insulin stimulates nitric oxide synthesis in human platelets and, through nitric oxide, increases platelet concentrations of both guanosine-30, 50-cyclic monophosphate and adenosine-30, 50-cyclic monophosphate. Diabetes 46: 742749.
  • Tsai C, Hayes C, Taylor GW (2002). Glycemic control of type 2 diabetes and severe periodontal disease in the US adult population. Community Dent Oral Epidemiol 30: 182192.
  • Tuomilehto J, Lindstrom J, Eriksson JG et al (2001). Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 344: 13431350.
  • Ujpa′l M, Matos O, Bı′bok G, Somogyi A, Szabo′ G, Suba Z (2004). Diabetes and oral tumors in Hungary. Epidemiological correlations. Diabetes Care 27: 770774.
  • UK Prospective Diabetes Study (UKPDS) Group (1998). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352: 837853.
  • UK Prospective Diabetes Study (UKPDS) Group (1998). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: (UKPDS 38). BMJ 317: 703713.
  • Van Den Berghe G, Wouters P, Weekers F et al (2001). Intensive insulin therapy in critically ill patients. N Engl J Med 345: 13591367.
  • Worthley MI, Holmes AS, Willoughby SR et al (2007). The deleterious effects of hyperglycemia on platelet function in diabetic patients with acute coronary syndromes: mediation by superoxide production, resolution with intensive insulin administration. J Am Coll Cardiol 49: 304310.
  • Writing Team for the DCCT / EDIC Research group (2002). Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 287: 25632569.